Nontuberculous Mycobacterial Infection Market 2024 - By Size, Industry Analysis, Segmentation And Outlook 2033

The new report published by The Business Research Company, titled Nontuberculous Mycobacterial Infection Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the nontuberculous mycobacterial infection market size has grown strongly in recent years. It will grow from $13.43 billion in 2023 to $14.25 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The nontuberculous mycobacterial infection market size is expected to see strong growth in the next few years. It will grow to $18.17 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp

Rising Prevalence Of Copd Fuels Growth In The Nontuberculous Mycobacterial Infection Market
The rising prevalence of chronic obstructive pulmonary disease (COPD) is expected to propel the growth of the nontuberculous mycobacterial infection market going forward. Chronic obstructive pulmonary disease (COPD) is a chronic respiratory condition characterized by persistent and often progressive lung airflow limitation. Nontuberculous mycobacterial (NTM) infections in patients with COPD are associated with a more significant decline in forced expiratory volume in one second (FEV1) and an increased exacerbation rate. COPD may weaken the immune system and damage the lung tissue, making it easier for NTM bacteria to infect the lungs. For instance, in March 2023, according to a report published by The Scottish Public Health Observatory (ScotPHO), a Scotland-based public health body, COPD rates began to climb between 2021 and 2022, with male rates increasing from 83.2 to 97.6 per 100,000 persons while female rates increased from 72.6 to 97.3. Therefore, the rising prevalence of chronic obstructive pulmonary disease (COPD) drives the growth of the nontuberculous mycobacterial infection market.

Adoption Of Innovative Treatment Approvals In The Nontuberculous Mycobacterial Infection Market
Major companies operating in the nontuberculous mycobacterial infection market adopt new treatment approval practices to sustain their position in the market. For instance, in June 2021, Paratek Pharmaceuticals Inc., a US-based pharmaceutical company, received approval to expand NUZYRA's (omadacycline) indication for treating community-acquired bacterial pneumonia (CABP) in adults. NUZYRA is a modernized tetracycline specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypical and other drug-resistant strains. Further, in July 2022, the Food and Drug Administration, a US-based federal agency, granted Fast Track designation for NUZYRA to treat nontuberculous mycobacterial (NTM) lung disease due to MAC (Mycobacterium avium complex).

The nontuberculous mycobacterial infection market covered in this report is segmented -

1) By Drug Class: Macrolides; Rifampin; Aminoglycoside; Other Drug Classes
2) By Route Of Administration: Oral; Parenteral; Other Routes
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13020&type=discount

Major players in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.

Contents of the report:
1. Executive Summary
2. Nontuberculous Mycobacterial Infection Market Report Structure
3. Nontuberculous Mycobacterial Infection Market Trends And Strategies
4. Nontuberculous Mycobacterial Infection Market - Macro Economic Scenario
5. Nontuberculous Mycobacterial Infection Market Size And Growth
…..
27. Nontuberculous Mycobacterial Infection Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/nontuberculous-mycobacterial-infection-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.